33 results
8-K
EX-99.1
CELU
Celularity Inc - Ordinary Shares
12 Feb 24
Regulation FD Disclosure
4:15pm
EXHIBIT 99.1
Description of Business
Celularity Inc. (“Celularity”) is a cellular and regenerative medicine company developing cryopreservable “off … of highly expandable allogeneic cells and structural tissue components, all focused on opportunities in cellular and regenerative medicine.
Celularity has
8-K
CELU
Celularity Inc - Ordinary Shares
17 Jan 24
Entry into a Material Definitive Agreement
4:14pm
-001 for regenerative indications).
The foregoing descriptions of the securities purchase agreement, the PIPE Warrants and the Dragasc investor
8-K
EX-99.1
CELU
Celularity Inc - Ordinary Shares
9 Jan 24
Celularity Announces Net Sales and Total Revenue Expectations
4:49pm
both cellular and regenerative tools for several clinical indications such as wound healing and orthopedics. Considering the financial challenges
8-K
EX-99.1
CELU
Celularity Inc - Ordinary Shares
7 Sep 23
Celularity Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors
4:21pm
and military physician-scientist with a strong background in regenerative medicine and a deep commitment to advancing healthcare, will bring invaluable … significant contributions to regenerative medicine and stem cell therapy, earning him recognition as a thought leader in these areas. He has published
8-K
EX-99.1
CELU
Celularity Inc - Ordinary Shares
29 Aug 23
Celularity Announces Multi-year Research Collaboration Services Agreement with Regeneron
9:15am
evolution in cellular and regenerative medicine by developing allogeneic cryopreserved off-the-shelf placental-derived cell therapies, including
8-K
EX-99.1
umhtplyf1dgzza3c
28 Jul 23
Celularity Inc. Announces $3 Million Registered Direct Offering
4:27pm
8-K
EX-99.1
3i9p hj5r4
27 Apr 23
Other Events
5:01pm
8-K
EX-99.1
d3m1p ns86g7p
6 Apr 23
Celularity Inc. Announces $6 Million Registered Direct Offering
8:58pm
8-K
EX-99.1
radlx
16 Dec 22
Other Events
8:38am
424B3
xqd297vmm2bvtjxo6g
1 Jun 22
Prospectus supplement
4:06pm
424B3
m4uom63h
3 May 22
Prospectus supplement
4:06pm
POS AM
tp093hm6n6 28l9r7
1 Apr 22
Prospectus update (post-effective amendment)
9:15pm